Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review assessed the clinical and cost-effectiveness of baricitinib, an oral treatment for severe alopecia areata in adults, to inform Canadian reimbursement recommendations, excluding Quebec.

Recognizing IPPP is crucial to prevent misdiagnosis and unnecessary treatments.

In this case report, a 28-year-old male with severe atopic dermatitis, prurigo nodularis-like lesions, and alopecia areata showed rapid improvements in skin and hair following treatment with the JAK1 inhibitor, ivarmacitinib, suggesting its potential benefit for complex AD phenotypes with immune-mediated hair loss.

This study found that N-acetylcysteine effectively prevented cyclophosphamide-induced alopecia in rats, and ImuVert plus N-acetylcysteine prevented alopecia from a cyclophosphamide-cytarabine combination.

This study reported a rare case of pityriasis rubra pilaris-like skin reaction in an 18-year-old woman after starting ponatinib treatment for relapsed Philadelphia chromosome-positive acute lymphoblastic leukemia, which resolved after treatment adjustment and did not recur over 15 months.

This study found that family actions such as preparing preferred foods and managing routines helped cancer patients manage chemotherapy side effects at home.

This case report describes a probable hypersensitivity reaction to a single intravenous dose of ondansetron, highlighting the need for cautious use, especially in outpatient settings.

This review compiles data on how the apelinergic system may protect against heart damage caused by doxorubicin cancer treatment, suggesting its potential to mitigate cardiotoxicity, though further research in chronic models is needed to confirm these effects and mechanisms.

This study observed that conjugates of the anticancer drug raltitrexed with dextran and albumin were more cytotoxic than the free drug at high concentrations, altering cell cycle effects.

This study found that the MD-3 antibody significantly improved the survival of hair follicle allografts in nonhuman primates by reducing T-cell infiltration.

Baricitinib can lead to hair regrowth in alopecia areata but may also cause relapses.

In this case study, a woman with alopecia areata experienced significant hair regrowth after starting ritlecitinib but developed an acneiform eruption, leading to the discontinuation of the drug and subsequent hair loss relapse; the eruption suggests a treatment-limiting adverse effect of JAK inhibitors.

This source concludes that repurposing existing drugs, such as using metformin with other treatments in advanced non-small cell lung cancer, may enhance cancer patient outcomes, although various technical and legal challenges need addressing.

This study analyzed safety data for semaglutide, liraglutide, and tirzepatide from the EudraVigilance database, identifying potential safety signals not listed in current SmPCs, such as optic ischemic neuropathy and pancreatitis, underscoring the importance of ongoing pharmacovigilance.

Abrocitinib may help treat alopecia areata effectively with mild side effects.

This study found that in a rat model, 14,15-EET may alleviate central poststroke pain by enhancing thalamic inhibition through neurosteroid signaling, potentially outperforming gabapentin in early-stage treatment.

This study introduced the KRDQN predictive framework, which outperformed existing methods in predicting adverse drug reactions and provided interpretable insights into drug mechanisms, aiding pharmacovigilance and clinical decision-making.

This study reports a case where a patient with both psoriasis and alopecia universalis experienced regrowth of scalp and body hair after treatment with Deucravacitinib, a TYK2 inhibitor, suggesting potential effectiveness but recommending controlled studies to confirm this finding.

This study reports that Asparagus racemosus and Withania somnifera extracts significantly reduced paclitaxel-induced myelosuppression and morbidity in mice, suggesting their potential as therapeutic adjuvants in cancer management.

In this study involving women undergoing taxane-based chemotherapy, a twice-daily topical application of BPM31543 was well-tolerated and showed potential in reducing severe hair loss, prompting further investigation at higher doses.

This article reviews numerous drug reactions and interactions for various medications and does not present new research findings.

In this animal study, agmatine exhibited a protective effect against seizures related to hormone fluctuations, with results suggesting that its anticonvulsant properties may involve interactions with central neurosteroids in female rats experiencing progesterone withdrawal.

This review discusses the roles and therapeutic effects of GLP-1 receptor agonists on the nervous, cardiovascular, and endocrine systems, but reports no new clinical results, emphasizing the need for further research on their impact on metabolism and tumor relationships in type 2 diabetes patients.

This study found that while glucagon-like peptide 1 receptor agonists report more incidents of suicide, hair loss, and aspiration compared to some other antidiabetic drugs, they did not meet the threshold for positive safety signals.

This study found that using urine tenofovir monitoring for PrEP adherence is well-accepted and may help overcome adherence barriers among participants at a U.S. urban clinical center.

In this study, four children with recurrent atypical teratoid rhabdoid tumors experienced disease stabilization or regression after treatment with alisertib, suggesting its potential role in future trials for this condition.

This review reports that the compound Cepharanthine shows promise as a cancer therapy by inducing cell death, arresting cell growth, inhibiting tumor progression, modulating key oncogenic pathways, and reversing multidrug resistance, suggesting its potential for further investigation in oncology.

In this case report, a woman experienced complete hair regrowth after anagen effluvium and lichenoid eruptions, possibly due to early corticosteroid intervention after INH was withdrawn.

This study reported that VCP combination chemotherapy achieved a complete response in 53% of advanced non-Hodgkin's lymphoma patients, although more intensive treatment may be needed for improved outcomes.